Baxter

Baxter is a global leader in innovative systems for dialysis

Based in IL

🤖

AI Overview

With $1.6M in lobbying spend across 20 quarterly filings, Baxter is a significant lobbying presence.

$1.6M
Total Lobbying Spend
20
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$320K
2019$320K
2020$320K
2021$320K
2022$320K

Lobbying Firms

TARPLIN, DOWNS & YOUNG, LLC

What They Lobby For

  • ESRD, innovation
  • ESRD, innovation, Medicare coverage and reimbursement Kidney Rx
  • ESRD, innovation, Medicare coverage and reimbursement, new tech add-on Kidney Rx
  • ESRD, innovation, Medicare coverage and reimbursement, new tech add-on Kidney Rx home dialysis
  • ESRD, innovation, Medicare coverage and reimbursement, new tech add-on Kidney Rx home dialysis H.R. 2710, Patient Access to ESRD New Innovative Devices Act
  • ESRD, innovation, Medicare coverage and reimbursement, new tech add-on, kidney care demonstrations Kidney Rx home dialysis H.R. 2710, Patient Access to ESRD New Innovative Devices Act
  • H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act
  • H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act H.R. 6800 - The Heroes Act
  • H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act H.R. 6800 - The Heroes Act H.R. 133 - Consolidated Appropriations Act, 2021
  • ESRD, innovation, Medicare coverage and reimbursement, new tech add-on, kidney care demonstrations Kidney Rx home dialysis H.R. 2710, Patient Access to ESRD New Innovative Devices Act H.R. 133 - Consolidated Appropriations Act, 2021

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.